2019
Siponimod Chips Away at Progressive MS
Longbrake EE, Hafler DA. Siponimod Chips Away at Progressive MS. Cell 2019, 179: 1440. PMID: 31951523, PMCID: PMC8023412, DOI: 10.1016/j.cell.2019.11.034.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisGadolinium-enhancing MRI lesionsInflammatory disease activityImmunomodulatory medicationsDisability progressionDisease activityMRI lesionsProgressive MSNeurologic disabilityPMS patientsMultiple sclerosisSiponimodMedicationsSclerosisPatientsLesionsBedsideProgression
2018
Effectiveness of alternative dose fingolimod for multiple sclerosis
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology Clinical Practice 2018, 8: 102-107. PMID: 29708225, PMCID: PMC5914753, DOI: 10.1212/cpj.0000000000000434.Peer-Reviewed Original ResearchProportion of patientsDaily doseMultiple sclerosisAlternate doseAdverse eventsDisease activityProfound lymphopeniaContrast-enhancing MRI lesionsAlternate dosingLiver function abnormalitiesClass IV evidenceDaily oral medicationContrast-enhancing lesionsBetter disease controlBreakthrough diseaseMRI lesionsRadiologic outcomesFunction abnormalitiesMost patientsOral medicationsRelapse rateFrequent dosingObservational studyFingolimodHigh risk